Skip to main content

Onco360 Announces Hiring of Bill Gittinger; National Director of Managed Care

Web Exclusives - Press Releases

New York – June 26, 2014 – Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business.

Mr. Gittinger will be joining an already accomplished Managed Care Sales team at Onco360, and will be responsible for supporting the continued growth of the company’s Healthcare Payer contracts.

“With over 25 years of healthcare experience that spans across industry segments, but with extensive focus on reimbursement and health economics, Bill Gittinger is a great fit for Onco360 as we look to help our Managed Care customers define meaningful strategies for better managing their cancer care spend,” said Burt Zweigenhaft, Vice Chairman of Onco360.

Mr. Gittinger has been areimbursement consultant for numerous manufacturers. Most recently, he worked with DC-based Kimbell & Associates as Vice President of Reimbursement & Health Economics. Mr. Gittinger also spent 10 years with Baxter, and has led reimbursement for Genzyme/Biomatrix, Smith & Nephew, Bionicare, and Regenesis.

Mr. Gittinger received his B.S. degree in Biology from the University of Cincinnati.

About Onco360®:
With executive offices in New York City, Onco360 ( is is the largest independent provider of Oncology Pharmacy services in the country. Onco360 was founded in 2003 as OncoMed, The Oncology Pharmacy, to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 dispenses through its network JCAHO-accredited OncoMed Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, made a significant strategic investment in Onco360. The partnership between PharMerica and Onco360 creates the only national oncology pharmacy and care management platform in the country, with the unique ability to service the localized needs of community- and hospital based-oncologists.

Onco360® | 410 Park Avenue, Suite 820 | New York, NY 10022

OncoMed is JCAHO-accredited & the dispensing pharmacy of Onco360

Related Items
Researchers Identify 4 Predictors of Transition to Chronic Opioid Use Based on Readily Available Opioid Regimen and Patient Factors
Web Exclusives published on February 26, 2018 in Clinical, Press Releases
Access Market Intelligence Introduces Online Glossary of Common Drug Related Terms and Acronyms as e-Book
Web Exclusives published on February 7, 2018 in Press Releases
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
Web Exclusives published on February 14, 2014 in Press Releases
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
Web Exclusives published on January 23, 2014 in Press Releases
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
Web Exclusives published on December 9, 2013 in Press Releases
Last modified: August 30, 2021